# US 2015/0105339 A1 · Methods for treating resistant diseases using triazole containing macrolides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105339 A1
- Document ID: US20150105339A1
- Status: Published application
- Kind: A1
- Application number: 14/309,202
- Filed: 2014-06-19
- Published: 2015-04-16
- Earliest claimed: 2008-10-24
- Assignees: Cempra Pharmaceuticals, Inc.
- Applicants: Cempra Pharmaceuticals, Inc.
- Inventors: Prabhavathi FERNANDES; David E. Pereira
- Web page: https://patentgrep.com/patent/US20150105339A1

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/424: condensed with heterocyclic ring systems, e.g. clavulanic acid
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- C07D 498/04: Ortho-condensed systems
- C07H 17/08: Hetero rings containing eight or more ring members, e.g. erythromycins
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating diseases caused at least in party by resistant bacteria.

## Claims

### Claim at position 1

-40. (canceled)

### Claim 41

A method for treating a disease in a host animal, where the disease is caused at least in part by one or more bacteria resistant to azithromycin or clarithromycin, or both, the method comprising the step of administering an effective amount to the host animal of a compound of the formula
or a salt thereof, wherein:
R10 is hydrogen or acyl;
W is H, F, Cl, Br, I, or OH;
A is CH2, C(O), C(O)O, C(O)NH, S(O)2, S(O)2NH, C(O)NHS(O)2;
B is C0-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, or C4-C10 alkenylalkynyl; and
C is hydrogen, hydroxy, acyl, acyloxy, sulfonyl, ureido, or carbamoyl, or alkyl, alkoxy, heteroalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted.

### Claim 42

(canceled)
